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Abstract
Background: Breast cancer cell lines are widely used tools to investigate breast cancer biology and to develop new
therapies. Breast cancer tissue contains molecularly heterogeneous cell populations. Thus, it is important to understand
which cell lines best represent the primary tumor and have similarly diverse phenotype. Here, we describe the development
of five breast cancer cell lines from a single patient’s breast cancer tissue. We characterize the molecular profiles,
tumorigenicity and metastatic ability in vivo of all five cell lines and compare their responsiveness to 4-hydroxytamoxifen (4-
OHT) treatment.
Methods: Five breast cancer cell lines were derived from a single patient’s primary breast cancer tissue. Expression of
different antigens including HER2, estrogen receptor (ER), CK8/18, CD44 and CD24 was determined by flow cytometry,
western blotting and immunohistochemistry (IHC). In addition, a Fuorescent In Situ Hybridization (FISH) assay for HER2 gene
amplification and p53 genotyping was performed on all cell lines. A xenograft model in nude mice was utilized to assess the
tumorigenic and metastatic abilities of the breast cancer cells.
Results: We have isolated, cloned and established five new breast cancer cell lines with different tumorigenicity and
metastatic abilities from a single primary breast cancer. Although all the cell lines expressed low levels of ER, their growth
was estrogen-independent and all had high-levels of expression of mutated non-functional p53. The HER2 gene was
rearranged in all cell lines. Low doses of 4-OHT induced proliferation of these breast cancer cell lines.
Conclusions: All five breast cancer cell lines have different antigenic expression profiles, tumorigenicity and organ specific
metastatic abilities although they derive from a single tumor. None of the studied markers correlated with tumorigenic
potential. These new cell lines could serve as a model for detailed genomic and proteomic analyses to identify mechanisms
of organ-specific metastasis of breast cancer.
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Introduction
Breast cancer is one of the leading causes of cancer death in
women. Breast cancer cell lines have been used widely to study
breast cancer biology, to screen new drugs and to identify
pathways leading to suppression of cancer growth and metastases.
The most commonly used breast cancer cell lines were established
decades ago [1,2], and only a few breast cancer cell lines have
been established more recently, mainly due to difficulties in
culturing breast cancer cells without surrounding stromal cells.
Breast cancer is recognized to be a molecularly heterogeneous
disease. Markers such as estrogen receptor (ER), progesterone
receptor (PR) and HER2 are used to make disease prognoses and
to select specific therapies. A large percentage of breast cancer
tumors express the estrogen receptor alpha (ERa). A common
treatment for patients carrying these tumors is the ER antagonist
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e55145
4-hydroxytamoxifen (4-OHT), but some of these tumors develop
resistance to the treatment. There are reports that up-regulation of
the HER2 receptor may mediate 4-OHT resistance in ER positive
tumors [3]. The p53 tumor suppressor protein is also a critical
mediator of the anti-proliferative and pro-apoptotic effects of
several treatments used for breast cancer. While there are several
reports indicating functional interactions between the ERa and
p53 pathways [4,5,6,7,8], the impact of these interactions during
anti-hormone treatments is still unclear.
The aim of this work was to study the correlation of ER, p53,
CD44 and CD24 expression with proliferation, tumorigenicity and
metastatic potential of breast cancer cells. To this end, we isolated
and cloned five human breast cancer cell lines from a single
primary breast cancer tumor derived from a single patient. We
characterized these cell lines that appeared to differ in their
tumorigenic and metastatic potential in immune compromised
nude mice. All breast cancer cell lines express low levels of ER and
HER2 receptor although their proliferation is not dependent on
estrogen. Here we show that low doses of 4-OHT (an estrogen
antagonist) induced rather than inhibited proliferation of these
breast cancer cells that were ER positive, HER2 receptor positive
and had non-functional p53. In the present work we analyzed the
newly developed breast cancer cell lines for their tumorigenicity
and metastatic potential in nude mice. These cell lines could serve
as an important model for detailed genomic and proteomic
analysis to identify mechanisms of organ-specific metastasis of
breast cancer.
Results
Cloning of Breast Cancer Cell Lines Derived from the
Same Tumor
Cell lines from a single primary invasive ductal breast
carcinoma of a 35 year old woman were established in tissue
culture as detailed in the Methods section. The original tumor was
an invasive ductal carcinoma, stage 1, without lymph node
metastases (0/15), described as diploid with a high proliferation
index. More than 50% of the original tumor cells expressed
estrogen receptors and/or progesterone receptors and HER2 in
formalin-fixed and paraffin-embedded tissue by IHC. The
standard method of assessing HER2 and ER status in breast
cancer tissue from patients in 1999 when the tumor was resected
was IHC at our institution.
Clones of several cell lines were produced from the primary
breast cancer tissue by limiting dilution and established as separate
cultures. Microscopically, all clones had homogenous ‘‘plasmacy-
toid’’ appearance (Figure 1A, B, C, D, E). Cells were adapted to
growth in serum free medium and split once a week at a ratio of
1:4. All assays were performed with cells maintained in serum-free
medium. Each breast cancer cell line was frozen starting from
passage five and was passed up to 50 passages in culture. The
doubling time for all clones is 24–36 hours.
Tumorigenicity of Human Breast Cancer Cell Lines
We evaluated the tumorigenicity of the breast cancer cell lines
by injecting 2.56106 cloned cells per mouse into groups of 8 or 9
nude mice in two separate experiments. We chose to inject a
rather high cell number to ensure that clones, which did not
produce tumors in nude mice, were truly non-tumorigenic. Five
clones were selected for further study because they differed
significantly in the tumorigenic potential. ARM-H was particularly
tumorigenic, inducing tumors in all mice in both experiments, and
ARM-X induced tumors in eight out of nine mice (Figure 2 A, B,
C, D). In contrast, the ARM-E cell line did not induce tumors in
any recipient mouse in either experiment. The two other clones
had intermediate degrees of tumorigenicity, inducing tumors in
some but not all mice. In addition we observed a significant
difference in the kinetic of tumor development in nude mice by
different breast cancer cell lines.
Two mice injected with ARM-H cells developed tumors at day
24 post injection with an average tumor size of 398 mm3
(Figure 2A and B). According to the local Institutional Animal
Care and Use Committee mice have to be euthanized before the
tumor exceeds the maximum allowable size (diameter ,1 cm).
Another 2 mice injected with the same ARM-H cell line were
sacrificed at day 35 with tumor size 305 mm3 (Figure 2A and B)
and the last mouse injected with ARM-H cell line was sacrificed
on day 60 with tumor size 332 mm3 (Figure 2 A, B).
ARM-X was the only other cell line that developed tumors of
critical size in nude mice before 60 days post injection. Two mice
injected with ARM-X cell line were sacrificed on day 40 with
mean tumor size 270 mm3. Three other mice injected with ARM-
X cell line were euthanized on day 60 with tumor size 250 mm3
(Figure 2A,B).
Two out of three mice injected with cell line ARM-G developed
tumors and 4 out of 5 mice developed tumors in the two respective
experiments (Figure 2A and B). ARM-G cell injection induced late
tumor development, but the tumor size increased dramatically in
the last 10 days before mice were sacrificed (day 60) with a mean
tumor size 340 mm3 (Figure 2A and B).
Two out of three mice injected with cell line ARM-C developed
tumors in experiment 1; and 3 out of 5 mice in experiment 2
(Figure 2A, B and C). The tumor size of mice injected with ARM-
C cell line on day 60 reached 200 mm3 (Figure 2A and B).
All cell lines also induced metastases, however to a different
extents and with a different target tissues including, skin, skeletal
muscles and lymph nodes. The important difference between the
cell lines was the number of enlarged and infiltrated lymph nodes.
The cell line ARM-H infiltrated on average 4 lymph nodes in each
mouse (Figure 2 C). The other three cell lines infiltrated on
average 1 or 2 lymph nodes. Importantly, there was a statistically
significant difference in tissue specific metastases of different breast
cancer cells. In mice injected with ARM-H cell line metastases
were detected in skeletal muscles, skin and lymph nodes in 4 out of
5 mice. In contrast, all five ARM-X injected mice, developed
tumors, but only 2 formed skin and lymph node metastases,
suggesting that the ARM-X cell line is less metastatic then the
ARM-H cell line. These results indicate that multiple clones of
human breast cancer cells differed in their ability to induce tumors
in nude mice, in the kinetic of tumor formation and metastatic
capacity.
Characterization of Breast Cancer Cell Lines Isolated from
Primary Breast Cancer Tissue
Histological analysis of breast cancer cells invading skin, muscle
and lymph nodes are presented in Figure 3A, B, C, D. IHC of the
control tissue from a different patient with breast cancer (used as a
positive control) showed conventional nuclear staining of ER
(Figure 4A). However, tumor tissue derived from a nude mouse
injected with ARM-H cells showed unusually scattered cytoplas-
mic staining for ER (Figure 4B).
All of the following studies were performed with breast cancer
cell lines that have only been cultured in vitro and never passed in
mice. IHC analyses for HER2 and ER in the cultured breast
cancer cell lines showed the same unusual phenotype observed in
the tumors from nude mice injected with breast cancer cell lines.
The control SK-BR-3 breast cancer cell line had classical
membrane staining of HER2 (Figure 5A) while our new breast
Characterization of Breast Cancer Derived Cells
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Figure 1. Phase contrast photomicrographs of breast cancer cell lines at sub confluent and confluent stages. (A) ARM-H (B) ARM-G (C)
ARM-E (D) ARM-X cell lines (magnification x200).
doi:10.1371/journal.pone.0055145.g001
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cancer cell lines had more uniform and diffuse cytoplasmic
staining (Figure 5C, D, E). As was expected, ER staining was
highly positive in MCF-7 cells (Figure 5B), but only faint in the
cytoplasm of the newly established breast cancer cell lines
(Figure 5C, D, E). All five clones showed low level of HER2 and
ER expression by IHC.
In addition, clone ARM-C was positive for carcinoembrionic
antigen (CEA) (data not shown).
To further characterize the molecular subtype of these breast
cancer cell lines and to prove their epithelial origin, we analyzed
expression of cytokeratins (CKs). The control MDA-MB-231
breast cancer cell line was strongly positive for CK8/18
(Figure 5A). All five breast cancer cell lines are positive for
CK8/18 to different extents, suggesting their luminal origin; cell
lines ARM-G and ARM-C (60–65% respectively) had the highest
expression (Figure 6 B, C, D, E, F) [2,9,10,11]. All five-breast
cancer cell lines were negative for CK5/6 (data not shown) but
expressed another breast specific antigen mammaglobin (Figure 6
H, I, J, K, L).
The summary of the tumorigenicity of the breast cancer cell
lines in nude mice and the percentage of cells staining positive for
the different antigens are shown in Table 1. We did not observe
any correlation between the expression of any of the studied
markers with the tumorigenicity.
We also examined cell surface receptors CD44/CD24, in the
most tumorigenic (ARM-H) and the least tumorigenic (ARM-E) of
the five cell lines. Using FACS analysis, both cell lines expressed
the CD44high/CD24low phenotype and there were no quantitative
differences in the levels of the two receptors expressed by either
cell line (Figure 7). Nor did the expression level differ from the
positive control breast cancer cell line MDA-MB-231 (Figure 7).
Another proposed marker of tumorigenicity is ‘‘side population’’
(SP) characteristic. The population of cancer cells that efflux
chemotherapy drugs and therefore account for resistance of cancer
to chemotherapy is identified as side population [12]. We
examined SP in the most tumorigenic clone (ARM-H), a non-
tumorigenic clone (ARM-E) and as a control we used a well-
known, highly tumorigenic breast cancer cell line, MDA-MB-231.
Figure 2. Breast cancer cell lines induce tumors in nude mice and metastasize to different organs. (A) Five female BALB/c nude mice
received an injection of different breast cancer cells. #-Time when mice were sacrificed. Day 60 is the end of the experiment, mice were sacrificed and
tumors were excised. (B) A comparison between different breast cancer cell lines in tumor growth in nude mice. The mean tumor size in each cell line
group was compared. (C) Metastases of breast cancer cell lines in injected nude mice (D) Summary table of tumorigenicity and metastatic potential of
breast cancer cell lines.
doi:10.1371/journal.pone.0055145.g002
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All three cell lines contained SP characteristics as shown by
incubation with Hoechst dye in the presence and absence of
blockers of dye exclusion (Figure 8). Verapamil and ATP depletion
(using sodium azide and deoxyglucose) block the dye exclusion
mechanism by inhibiting the function of the P-glycoprotein
transporter and the other ABC transporters respectively [13].
However we did not perform sorting of the side population from
newly established breast cancer cell lines to determine the direct
Figure 3. Photomicrographs of H&E stains of human breast cancer cell lines and metastatic tumors from mice. (A) ARM-H (middle,
506) shows focal residual skeletal muscle (arrow) almost completely replaced and infiltrated by invasive adenocarcinoma (between asterisks); (right,
2006) the same area shows sheets of markedly atypical and pleomorphic carcinoma cells with numerous mitotic figures in a haphazard growth
pattern. (B) ARM-G (middle, 506) lymph node with deposits of metastatic tumor cells within the peripheral sinuses and parenchyma (arrows); (right,
2006) same lymph node with numerous scattered metastatic tumor cells; tumor cells show enlarged nuclei, significant atypia and pleomorphism
when compared to the surrounding normal lymphocytes, arrows indicate deposits of tumor cells. (C) ARM-C (middle, 506) shows sheets of
adenocarcnoma cells (between asterisks) invading into adjacent skeletal muscle (arrow); (right, 2006) view of the same area shows markedly
pleomorphic and atypical tumor cells with areas of tumor cell necrosis (arrow). (D) ARM-X (middle, 506) skin (arrow on epidermis), underlying adnexal
structures and dermis completely replaced by invasive adenocarcinoma entrapping sweat glands and normal follicles; (right, 2006) the same section
showing the markedly atypical tumor cells with mitoses, pleomorphic nuclei, and high nuclear to cytoplasmic ratio invading the dermis and
surrounding adnexal structures (triangle); arrow indicates skin adnexal structures.
doi:10.1371/journal.pone.0055145.g003
Characterization of Breast Cancer Derived Cells
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correlation of SP with tumorigenicity since the level of SP in
tumorigenic (ARM-H) and –non-tumorigenic (ARM-E) cell lines
was comparable (23.3%–21.1%).
HER2 Gene Amplification
Amplification of the HER2 gene has been shown to be both a
prognostic and predictive marker in the outcome of breast cancer
disease [14,15]. To determine whether the HER2 gene was
amplified in the newly established breast cancer cell lines, we used
FISH. (Because primary breast cancer tissue was no longer
available, the assay was not performed on original patient breast
cancer tissue). The HER2 gene which is localized on chromosome
17 region 17q11.2-12 was labeled red and the centromere of
chromosome 17 labeled green. A normal cell exhibits two signals
for each color and a ratio of HER2 to Centromere 17 is normally
1.0. If there is HER2 gene amplification, multiple copies of HER2
signals are observed.
The amplification ratio of all our breast cancer cell lines ranged
from 0.7–0.8. A ratio of less than 1 means that there were more
Centromere17 signals than HER2 signals (Figure 9A, B, C, F). As
was expected, the control breast cancer cell line SK-BR had HER2
amplification with a ratio of 5.6 which is consistent with HER2
gene amplification reported for this cell line (Figure 9D, F) [16,17].
All cancer cells have two normal HER2 signals on chromosome
17. The average numbers of HER2 signals per cell for cell lines
ARM-C, ARM-X, ARM-G and ARM-E were 3.3, 2.1, 2.1, and
2.2 respectively (Figure 9A, B, C, F). However, metaphase FISH
from cell line ARM-H revealed two additional centromere 17
signals that lacked the HER2 gene (Figure 9 A, E). Metaphase
FISH from cell lines ARM-G and ARM-E also revealed one
additional centromere 17 signal that lacked the HER2 gene
(Figure 9B, C, E, F). The number of chromosomes in each cell line
was distinct and varied from 51 for cell line ARM-G to 59 for cell
line ARM-C (Figure 9G).
Aberrant p53 Tumor Suppressor Gene Expression and
Function
It has been proposed that a CD44high phenotype correlates with
over-expression of mutated p53 in tumor tissue [18,19], suggesting
that inactivated p53 expression can aid the survival of immortal-
ized, premalignant cells and may also correlate with the level of in
vivo tumorigenicity of breast cancer cells [19,20]. To test the
likelihood of this correlation, we measured p53 mRNA expression
by real-time PCR in our five breast cancer cell lines, and as a
control we used normal breast epithelial cells and two other breast
cancer cell lines. Expression of p53 mRNA was up-regulated in the
tumorigenic MDA-MB-231, as well as in the non-tumorigenic
MCF-7 compared to normal breast epithelium (Figure 10A).
However, in the cell lines isolated from the patient’s breast cancer
tissue, mRNA levels were close to normal regardless of their
tumorigenicity status (Figure 10A). By RT-qPCR, we also showed
lower expression of p21 mRNA in all newly established breast
cancer cell lines regardless of tumorigenicity status compared to
normal breast epithelial cells isolated from the same patient donor
(Figure 10B).
Next we studied whether p53 is functional. In the presence of
functional p53, treatment of cells with the DNA-damaging agent
etoposide would up-regulate p21 protein. As a positive control for
functional p53 we used the MCF-7 breast cancer cell line. As
expected in the MCF-7 cell’s p21 protein level was up-regulated in
response to etoposide-treatment (Figure 10C). By contrast, even
though high levels of p53 protein appear to be present in our
newly derived cell lines, etoposide treatment failed to induce p21
protein-expression (Figure 10C), suggesting that p53 is present at
low levels and non-functional in the cells lines derived from the
patient’s tumor.
Mutational analyses of the TP53 tumor-suppressor gene
revealed the presence of two single nucleotide alterations. In exon
three of all five cell lines, there was a homozygous single nucleotide
alteration (ID# rs1042522) where cytosine in position 215 was
replaced by guanine (C215G), which leads to a change of amino
acid proline in position 72 to arginine (P72R) [21]. There was also
another heterozygous single nucleotide alteration detected in all
five cell lines. In exon seven of the TP53 gene, guanine at position
797 was substituted by adenine (G797A) leading to a change of
amino acid glycine at position 266 to glutamic acid (G266E).
These alterations in the TP53 gene lead to changes in amino acid
sequence of the p53 protein and together with functional assay
data indicate presence of mutated, non-functional p53 gene in the
patient’s breast cancer cell lines.
Effect of Tamoxifen on Growth of Breast Cancer Cell Lines
Estrogen receptor (ER) belongs to a family of nuclear hormone
receptors. It plays a key role in regulating growth, differentiation,
and tumorigenesis of breast cancer cells when activated by its
Figure 4. IHC stain of ERa in tumor isolated from nude mice. (A) positive control human breast cancer tissue, (B) tumor from breast cancer cell
line ARM-H derived from nude mice, arrows indicate negative mouse nodules.
doi:10.1371/journal.pone.0055145.g004
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ligand estrogen. There are two known isoforms of estrogen
receptor: ERa and ERb. We used antibodies to determine ERa
expression in breast cancer cell lines and tumors derived from
nude mice injected with our cell lines.
Cell lines ARM-C, ARM-E ARM-G and ARM-X expressed
nearly similar levels of ERa, only the most tumorigenic cell line
(ARM-H) showed less expression of ERa by western (Figure 11A).
Next we tested whether estradiol (E2) could stimulate the
expression of the ER target gene c-Myc. We tested relative level
of c-Myc expression by RT-qPCR after treatment of with 10 nM
of E2 for 24 h. As was expected, the MCF-7 cell line responded to
E2 treatment by robust up-regulation of c-Myc gene expression
(Figure 11A) E2 treatment of cell lines ARM-C, ARM-E and
ARM-G triggered moderate expression of c-Myc, whereas cell
lines ARM-H and ARM-X failed to activate c-Myc gene
expression (Figure 11A).
We next asked whether the ERa antagonist tamoxifen (a
common treatment used for breast cancer patients with ERa-
positive tumors) had any effect on proliferation of these cell lines.
As a positive control we used the MCF-7 breast cancer cell line
known to be tamoxifen-sensitive. As was expected, growth of
MCF-7 cells was inhibited by high concentrations of tamoxifen
(Figure 11B). Interestingly, both non-tumorigenic and tumorigenic
ARM breast cancer cell line proliferation was suppressed by high
concentrations of tamoxifen. Strikingly, low levels of tamoxifen
(100 nM-200 nM) actually induced growth of the newly estab-
lished breast cancer cells while they did not have any effect on
proliferation of MCF-7 cell line (Figure 11C and D).
Discussion
It is well known that there is great heterogeneity in the antigenic
and tumorigenic properties of individual tumor cells within
primary lesions of cancer, and there is an ongoing effort to
identify individual characteristics of the cells that correlate with
their ability to be tumorigenic xenograft models such as
immunodeficient nude mice. In this study, we minimized
confounding factors by isolating and cloning five cell lines of
human breast cancer cells derived from a single primary breast
cancer tumor from one patient. Our study confirmed the high
level heterogeneity in the pattern of antigen expression and
tumorigenicity in the different clones that were all derived from
the same primary breast cancer tumor. In human breast cancer
several characteristics have been suggested as markers of
tumorigenicity. These include, ‘‘side population characteristics’’
profile (SP), high expression of CD44 along with low expression of
CD24 [22], high expression of HER2 [23] and inactivation and/
or high level of expression of p53 [18,19,24] with low levels of p21
[25]. In studies designed to determine side population profile it is
known that Verapamil blocks the P-glycoprotein transporter and
sodium azide in combination of deoxyglucose blocks the dye
exclusion mechanism by inhibiting the function of the other ABC
transporters including breast cancer resistance protein (BCRP;
ABCG2) respectively [13]. In our experiments MDA-MB-231 cell
line treatment with verapamil completely blocks die exclusion
suggesting that these cells express P-glycoprotein transporter.
However in both newly derived breast cancer cell lines ARM-H
and ARM-E verapamil only partially blocks die exclusion
suggesting the presence of other ATP dependent transporters in
addition to P-glycoprotein transporter. Moreover ATP depletion
of the non tumorigenic cell line ARM-E significantly blocks die
exclusion (57%) however in the most tumorigenic cell line ARM-H
ATP depletion only partially (28%) blocks die exclusion suggesting
the presence of other types of transporters.
Importantly, in our hands there were no correlations between
any of the above-mentioned characteristics and the tumorigenic
potential in our newly established breast cancer cell lines.
We could furthermore demonstrate different organ specific
metastatic ability of breast cancer cell lines. However, more studies
are required, including characterization of expression of different
chemokine receptors by breast cancer cell lines, to understand the
mechanisms of organ-specific metastatic ability of cancer cell lines.
To test whether the HER2 gene was amplified in the patient’s
cancer cell lines, we used the FDA approved clinical -FISH test.
The HER2 gene was not amplified in all five breast cancer cell
lines, however it was rearranged. This rearrangement may
Figure 5. Photomicrographs of IHC stain of ER and HER2
expression and western blotting analyses of ER-expression and
response to E2 in breast cancer cell lines. (A) SK-BR-3 (B) MCF-7 (C)
ARM-H (D) ARM-G (E) ARM-E cell lines.
doi:10.1371/journal.pone.0055145.g005
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possibly lead to the unusual scattered cytoplasmic staining of the
HER2 protein.
The loss of function of tumor-suppressor gene TP53 is the most
common abnormality in a number of human cancers. Our cell
lines showed homozygous (P72R) and heterozygous (G266E) single
nucleotide alterations in all five breast cancer cell lines. The single
nucleotide alteration of p53 at codon 72 is common and unique to
humans. Reports of diminished Mdm2-mediated degradation of
altered p53 codon 72R (arginine) compared with p53-72P
(proline), [26] correlates with our data that p53 protein was
over-expressed in our cell lines. In addition, all cell lines carry
another single nucleotide alteration (G797A) leading to replace-
ment of glycine at position 266 to glutamic acid (G266E). This
single nucleotide alteration is located in the DNA binding domain
of the protein and could most likely be responsible for disrupting
normal p53 protein function. Concurrent with this result, we
found an inability of p53 to induce p21 protein in response to
DNA damaging agent in all five-breast cancer cell lines. We also
showed no induction of total p53 protein in response to etoposide
treatment in the MCF-7 cell line, which is in agreement with
published results on up-regulation of only phosphorylated p53
protein in response to etoposide treatment [27].
Single nucleotide alteration of TP53 (ID# rs1042522, P72R)
has been correlated with reduced disease free and overall survival
in women with breast cancer [28]. TP53 codon P72R has even
been suggested to be used as a marker to screen individuals at a
high risk for breast and pancreatic cancer [28,29,30]. This single
nucleotide alteration has also been associated with several other
cancers including glioma, prostate, non-small cell lung cancer
[31,32,33,34], and childhood acute lymphoblastic leukemia [35].
Single nucleotide alteration of the TP53 gene in the DNA binding
domain of exon seven G797A (G266E) has been documented for
MDA-MB-435 lines. However, another single nucleotide alter-
ation that we observed (ID# rs1042522, P72R) has not been
reported for any of the 41 studied breast cancer cell lines [36,37].
There are reports of positive therapeutic responses to 4-OHT
treatment in patients with ER-positive breast cancer who carry
wild-type p53 [38]. We used the patient’s ER positive cell lines
that have mutated p53 to study their response to 4-OHT. The
growth of tumorigenic ARM-H cell line (with low expression of
ER and not responding to E2 treatment by target gene c-Myc
stimulation) as well as non-tumorigenic cell lines ARM-E (with
high expression of ER and responding to E2 treatment by c-Myc
gene induction) was suppressed in response to high doses (5–2 mM)
but enhanced at low doses (0.1–0.2 mM) of 4-OHT treatment.
It has been reported that the mechanisms of tamoxifen
cytotoxicity differ in ER-positive and ER-negative breast cancer
cells [39]. Inhibition of proliferation in breast cancer cell line
ARM-E by high concentration of 4-OHT could be due to the
classical ER antagonist pathway accompanied by changes in cell
cycle kinetic parameters. However in cell line ARM-H inhibition
of cell proliferation by high doses of 4-OHT could be a result of 4-
OHT induced defects in nuclear division and accumulation of cells
in S phase in agreement with other published data [39].
Stimulation of cell proliferation in response to low doses of 4-
OHT is an interesting observation, which could be due to the
presence of non-functional p53 failure to regulate p21 in ARM-E
cell line carrying functional ER. Our data are in agreement with
recent publications showing (non-functional) p53-status dependent
breast cancer cell proliferation after treatment with 4-OHT [5,38].
However breast cancer cell lines used in these previous studies
were all estrogen-dependent in contrast to our cell lines that are
estrogen-independent. The authors proposed that loss of p53
function might increase the cross-talk between the ER and the
Figure 6. Photomicrographs of IHC stain of CK8/18 and mammaglobin for breast cancer cell lines. (A) MDA-MB-231, (B) ARM-E, (C) ARM-
X, (D) ARM-H, (E) ARM-G, (F) AMR-C; mammaglobin G) MDA-MB-231, (H) ARM-E, (I) ARM-X, (J) ARM-H, (K) ARM-G, (L) AMR-C (magnification 4006).
doi:10.1371/journal.pone.0055145.g006
Table 1. Summary of the results for tumorigenicity and percentage of expression of different antigens in breast cancer cell lines.
Cell lines MCF7 MDA-MB-231 ARM-C ARM-E ARM-G ARM-H ARM-X
Tumorigenicity, two
experiments (%)
n/d n/d 62% (5/8) 0 75% (6/8) 100% (9/9) 88%
(8/9)
CK8/18 (%) 100% 100% 25% 5% 35% 5% 10%
Mammaglobin (%) 1% 60% 65% 10% 60% 1% 5%
ER (%) 100% n/d 5%* 10%* 15%* 5%* 5%*
Her2 (%) 1% n/d 10% 5% 5% 15% 10%
*Indicates scattered cytoplasmic staining.
doi:10.1371/journal.pone.0055145.t001
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EGFR/HER2 pathways, thus contributing to a proliferative effect
of 4-OHT. The mechanism of stimulation of proliferation in
response to 4-OHT could be different in ARM-H cell line carrying
non-functional ER. A growing number of reports regarding effects
of E2 cannot be explained by the classical model of E2 action,
which involves the binding to ERs and the interaction of the E2-
ER complex with specific DNA sequences linked to E2 target
genes. There are several reports from different groups reporting
proliferation in response to tamoxifen in ER-negative cells, which
is mediated by G protein-coupled receptor GPR30/GPER-1
(GPER-1) [40,41,42]. Our cell line with low expression level of ER
(ARM-H) showed increased proliferation in response to 4-OHT,
possibly suggesting a recruitment of G protein-coupled receptor
GPR30/GPER-1 (GPER-1). However, more experiments (includ-
ing silencing of GPR30/GPER-1 with RNAi) are required to
determine the exact mechanism of ER negative breast cancer cell
proliferation in response to 4-OHT.
Contrary to current thinking, binding of 4-OHT to ER in breast
cancer cells could induce rather than inhibit cancer cell
proliferation in settings where the p53 protein is mutated and is
present along with amplified or mutated HER2/neu receptors.
This includes cases when ER receptors are present but tumor
growth is not estrogen dependent. Our findings and reports from
other groups suggest that more studies are required to further
address the relevance of mutated p53 and HER2/neu in the
regulation of the ERa pathway.
In the present work we performed an extensive characterization
of the newly developed ARM breast cancer cell lines. Given their
different metastatic potential, they could serve as a good model for
detailed genomic and proteomic analysis to identify mechanisms of
organ-specific metastasis of breast cancer.
To study interactions of human cancer tissues with the host
environment, an in vivo nude mice system has become a valuable
tool in breast cancer research. However, the most widely studied
metastatic models of xenografts from established breast cancer cell
lines have been developed by several in-vivo passages [43].
Passaging cancer cells in nude mice will alter their phenotype by
exposing them not only to mouse mammary tumor virus but to
other mouse pathogens as well. This could potentially alter not
only the metastatic capacity but also the antigenic profile of cells to
the level that in vivo-passaged human breast cancer cells fail to
represent true human breast cancers. In contrast, these five newly
Figure 7. Expression of CD44/CD24 receptors on breast cancer cells. The plots depict CD44, CD24 and an isotype control antibody staining
of ARM-H, ARM-E and control MDA-MB-231. This is one representative experiment of three independent experiments.
doi:10.1371/journal.pone.0055145.g007
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developed breast cancer cell lines were never passaged in mice and
display a very different tumorigenic and metastatic potential. Thus
these breast cancer cell line xenografts can provide valuable tools
to study various important interactions between the tumor and
host tissues, including endocrinologic, immunologic, and tumor-
stroma interactions.
Materials and Methods
Reagents, Hormones, and Antibodies
17-Estradiol (E2), 4-hydroxy-tamoxifen (OHT) and all other
reagents were purchased from Sigma (St. Louis, MO) unless
otherwise indicated. Antibodies used: HER2/neu (Clone L87),
carcinoembrionic antigen (CEA) (clone COL-1), epithelial mem-
brane antigen (EMA) (clone VU 4H5), Epithelial Specific Antigen
(ESA) (clone VU-1D9) (all from NeoMarkers, Fremont, CA), anti-
p21 monoclonal antibody clone SXM30 (BD Pharmingen), anti-
Glyceraldehyde-3-Phosphate Dehydrogenase, (GAPDH) clone
6C5 Antibodies (Millipore, Temecula, CA).
Isolation and Cloning of Human Breast Cancer Cell Lines
This study was conducted using adherence to Helsinki
Declaration guidelines. Collection of breast cancer tissue was
approved by the New York University School of Medicine
Institutional Review Board and was done in accordance with the
ethical guidelines for use of human specimens.
The tissues were rinsed in HBSS containing 100 mg/mL
gentamicin, 200 U/mL penicillin, 200 mg/mL streptomycin (all
from Invitrogen, Carlsbad, CA), dissected into small pieces and
digested for 1 h at 37uC with an enzyme mixture comprised of
200 mg/mL collagenase type III (Worthington Biochemical
Corporation, Lakewood, NJ) and 1 mg/mL dispase (Boehringer
Mannheim, Indianapolis, MN) in HBSS. The digested cells were
washed X 3 with 1:1 dilution of 15 ml HBSS and Ham’s F12
medium (Mediatech, Inc, Herndon, VA); then suspended in
Ham’s F12 medium supplemented with 10% FBS, 200 U/mL
penicillin, 200 mg/mL streptomycin, and 2 mM L-glutamine. The
cells were plated in 6-well tissue culture plates that were coated
with collagen type I (Collaborative Biomedical, Bedford, MA).
Once cells grew continuously, the concentration of FBS was
gradually reduced step-wise every 4 weeks until the cells were fully
adapted to long-term growth in serum-free F-12 medium
supplemented with 5 mg/mL transferrin (Sigma, St. Louis, MO),
5 mg/mL insulin (Novo Nordisk, Princeton, NJ), 1 mg/mL
hydrocortisone, 50 ng/mL triiodothyronine, 20 ng/mL b-estradi-
ol and 30 ng/mL progesterone (all from Sigma).
Fluorescent In Situ Hybridization (FISH) for HER2 Gene
Amplification and Determination of Number of
Chromosomes in Breast Cancer Cell Lines
Interphase and metaphase cells were obtained from cultures
using standard cytogenetic methods. Fluorescence in situ hybrid-
ization (FISH) analysis was performed as previously described with
pepsin modification treatment (100 uL 10% pepsin and 2 mL 1%
HCl) for five minutes [44]. Codenaturated DNA from cells was
hybridized with FISH probes using two DNA probes, HER2
(17q11.2-12) and CEP17 (17p11.1-q11.1 Alpha Satellite DNA) in
Thermobrite (Abbott Molecular, Des Plaines, IL) for three minutes
at 73uC and hybridized at 37uC overnight. This is an FDA
Figure 8. Side population profile of breast cancer cell lines ARM-H, ARM-E and control MDA-MB-231. The side-population cells are
indicated in enclosed boxes and the percentage of the cells in this region is indicated in each panel. These data are representative of two
independent experiments.
doi:10.1371/journal.pone.0055145.g008
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Figure 9. Representative metaphase (left) and interface (right) from four-breast cancer cell lines. Each cell nucleus contains HER2 signals
(red) and centromere 17 signals (green). (A) ARM-H (B) ARM-G (C) ARM-E and (D) SK-BR-3; (E) composite karyotype of chromosome 17 and derivatives
in four cell lines; (F) summary table of FISH analyses; (G) number of chromosomes in breast cancer cell lines.
doi:10.1371/journal.pone.0055145.g009
Figure 10. mRNA expression level and western blotting analyses of p53 and p21. RNA was isolated from breast cancer cell lines, converted
into cDNA, followed by q-PCR with (A) p53 or (B) p21 specific primers. Relative mRNA expression was calculated after normalization to the ribosomal
protein (RPS11) control gene. Each experiment was done at least three times. Data represent mean 6 SD. ANOVA one-way statistical analyses was
used to compare results *p,0.05 considered statistically significant; (C) western blotting analyses of breast cancer cells treated with 5 uM of
etoposide for 24 h followed by protein extraction, gel electrophoresis and antibody staining for indicated proteins.
doi:10.1371/journal.pone.0055145.g010
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approved clinical test. A total of 50 nuclei were scored in each of
the 6 cell lines and the HER2 gene amplification was calculated as
per manufacturers instructions. To determine the number of
chromosomes, five metaphase cells were randomly chosen from
each cell line and the number of chromosomes was enumerated.
Tumorigenicity Assay
The animal protocol was approved by the Institutional Animal
Care and Use Committee of New York University School of
Medicine and Mount Sinai School of Medicine in compliance with
internationally recognized animal guidelines. 2.56106 cells of each
line suspended in 150 mL of phosphate-buffered saline (PBS) were
injected subcutaneously into the flanks of 4-week-old athymic
female Nu/nu mice (Charles River Laboratories, Wilmington,
MA) or from Taconic Farms Inc, NY, without implanting human
estrogen patches. The animals were maintained for four to six
weeks in 1st experiment and eight weeks in 2nd experiment.
Animals were palpated weekly for tumor appearance. Tumor
volumes were calculated with the following formula: tumor volume
(mm3) = 0.56length (mm)6width2 (square mm). When tumor
nodules reached 0.5–2 cm in size, mice were euthanized by
exposure to CO2, tumors were excised and histology was
performed at the NYU and Mount Sinai Pathology Core Facility
in New York City.
Detection of Side Population
Side population (SP) characteristics were analyzed based on the
ability of the cells to exclude Hoechst 33342 dye [13]. Briefly, cells
were re-suspended at 16106/mL in pre-warmed F12 medium
with 2% FCS, 5 mg/mL Hoechst 33342 dye and with or without
50 mg/mL verapamile or 50 mg/mL deoxyglucose (Sigma) and
incubated at 37uC for 90 min.
Western Blot Analyses
For immunophenotyping, cell lysate was electrophoresed and
the proteins transferred to PVDF-membrane then probed with
monoclonal antibodies directed to breast cancer associated
antigens. Strips of membrane were then incubated with monoclo-
nal antibody against HER2/neu (Clone L87), carcinoembrionic
antigen (CEA) (clone COL-1), or epithelial membrane antigen
(EMA) (clone VU 4H5) (all from NeoMarkers, Fremont, CA)
according to manufacturer’s protocol. The membranes were
washed in TBS (Sigma) containing 0.1% tween 20 followed by
incubation with HRP- labeled secondary antibodies (Sigma)
according to manufacturer’s instructions. Proteins were visualized
using enhanced chemiluminescent ECL substrate (Amersham
Pharmacia, Piscataway, NJ) as per the manufacturer’s instructions.
For the etoposide assay, protein extracts were prepared by
lysing cells with RIPA- buffer (Pierce) containing proteases
(Pierce). Equal amounts of total proteins were separated on a 4–
10% SDS-PAGE gel (Invitrogen) and transferred to a PVDF-
membrane (Invitrogen). Anti-p21 monoclonal antibody clone
SXM30 (BD Pharmingen). Anti-Glyceraldehyde-3-Phosphate
Dehydrogenase, (GAPDH) clone 6C5 Antibodies (Millipore,Te-
mecula, CA). Protein signals were revealed using AmershamTM
ECL western-blotting Detection Reagents and AmershamTM
Hyperfilm ECL. Anti-HER2/neu Ab-20 clone L87+2ERB19 and
anti-P53 (clone DO-7+BP-12) (Thermo scientific, Fremont, CA).
Each experiment was repeated at least twice.
TP53 Gene Mutation Screening
Cells were grown to 70–80% confluence, total genomic DNA
was isolated using the QIAamp DNA Blood mini Kit (Qiagen).
Genomic DNA isolated from 5 different breast cancer cell lines
was used to analyze the coding region of human TP53 gene for
mutation analysis by sequencing (TP53; NCBI GeneID: 7157;
NM_001126112.1; CCDS 11118.1, Builds 35.1–37.1), with
sequence analysis across the coding ten exons including 10 bp 59
and 39 intron sequence, covered by up to 13 amplicons (average
400 bp per amplicon). PCR reaction was cleaned-up, double
strand sequencing with PCR primers was used and data was
analyzed based on variants: NM_001126112.1, NM_000546.4,
NM_001126113.1 and NM_001126114.1, NM_00126115.1,
NM_00126116.1 and NM_00126117.1 by Genewiz (South
Plainfield, NJ).
Flow Cytometry
Expression of CD44 and CD24 receptors was analyzed by
FACS. The cells were harvested with 0.05% trypsin (Invitrogen),
washed and incubated with anti-human CD44 (Sigma, clone
c7923) or anti-human CD24 antibodies (Becton Dickenson
Biosciences, San Jose, CA) or isotype control antibodies (mouse
immunoglobulin) (Sigma). Cells were stained similarly for expres-
sion of HER2/neu (Clone 9G6.10), CEA (clone COL-1), and
Figure 11. Breast cancer cell lines express different levels of estrogen receptor and respond differently to estrogen and 4-OHT
treatments. (A) bottom. Western blotting analyses of breast cancer cells for ER expression and top RT-qPCR for cMYC gene expression in RNA
extracted from indicated cells treated with 10 nM of E2 for 24 h. (B) Cytotoxicity assay of MCF-7, (C) ARM-E and (D) ARM-H breast cancer cells treated
for 3 days with different concentrations of 4-OHT. Left axis represents the relative percentage of live cells treated with 4-OHT compared to medium-
treated cells. Similar results were obtained in three independent experiments. Data represents mean 6 SD. Student’s t test was used to compare
means of treated versus untreated samples with *p,0.05 considered statistically significant.
doi:10.1371/journal.pone.0055145.g011
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Epithelial Specific Antigen (ESA) (clone VU-1D9) (all from
NeoMarkers, Fremont, CA) and for expression of NKI/C3
(Monosan, Netherlands). Fluorescence was detected using a
FACScan (BD Immunocytometry Systems, San Jose, CA) and
analyzed using FlowJo software (Tree Star, Beckman Coulter,
Fullerton, CA).
Hematoxylin and Eosin (H&E) Staining
Breast cancer cell line clots were prepared by the addition of
equal parts of thrombin and fibrin (expired platelets from the
blood bank) followed by resuspension and cytocentrifugation to a
form cell pellet. The clots were fixed in 10% neutral buffered
formalin, processed, sectioned and stained with H and E using
standard protocols.
Immunocytochemistry (IHC)
AgarCyto cell blocks were prepared based on the method of
Kerstens et al., [45] using agar as an intermediate embedding
medium. Breast cancer cells were briefly fixed in 10% neutral
buffered formalin and resuspended in 0.3 mL of 2% liquid agarose
at 65uC. The solidified agar–cell pellet was then embedded in
paraffin. Slides were cut at 4 microns, baked at 90uC and stained
according to manufacturers’ recommendations. Detection anti-
bodies included mammagloblin clone 31A5 (Cell Marque), CK 8/
18, clones B22.1 and B23.1, CK 5/6 clones D5, 16B4 (Ventana
Medical Systems) and HER2/neu Clone L87 (NeoMarkers,
Fremont, CA). Visualization was done using the Ventana iView
DAB Detection kit followed by counter-staining with Harris
Hematoxylin.
Immunostaining for CK8/18, mammaglobin, ER and Her2
antigens for each cell line was evaluated for both staining intensity
and percentage of positive epithelial cells in five randomly selected
areas.
Real-time PCR
RNA was isolated from 16107 cells using 1 mL of TRIzol
(Invitrogen) followed by DNase I treatment (Qiagen) according to
manufacturer’s instructions. cDNA synthesis was done by using
oligo-dT primers and an Omniscript reverse transcription kit
(Qiagen). PCR primer sequences for p53, p21 and ribosomal
protein S11 (RPS11) were as follows (forward and reverse,




and 59-ATGTCCAGCCTCAGAACTTC-39). Quantification of
gene expression was based on the threshold cycle (CT-value),
defined as the first cycle number with detectable fluorescence
above background. Relative quantification of specific gene
expression was calculated by comparing CT-values of individual
genes after normalizing to a reference - gene ribosomal protein.
Real time PCR for mRNA expression profiles were performed on
total RNA isolated from cells. Primers and kits for preparation of
cDNA were from Qiagen company (Valencia, CA). All mRNA
transcripts were measured by RT-qPCR where fold change in
mRNA expression of breast cancer cells was calculated as
compared with normal breast epithelial cells after normalization
to the ribosomal protein (RPS11) control gene. Each experiment
was done at least three times. Data represent mean 6 SD.
Student’s t -test was used to compare means of treated versus
control samples. P,0.05 was considered to be statistically
significant.
Cell Proliferation Assays in Response to Different
Treatments
17b-Estradiol (E2), was purchased from Sigma (St. Louis, MO)
unless otherwise indicated. The effect of 17b-estradiol (E2) and 4-
hydroxy-tamoxifen (OHT) treatments on cell proliferation was
analyzed using an MTS assay (CellTiter 96R AQueousOneSolu-
tion, Promega) and cells were counted with trypan blue in 96-wells
flat bottom plates according to the manufacturer’s protocol. Cells
were plated in the presence of estrogen or in estrogen-deficient
medium for 24 h and increasing doses of OHT were added for 3
days. The relative percentage of living cells under these treatments
was compared to medium-treated cells. To determine viable cells,
three different experiments were performed in triplicates for each
treatment. To obtain the relative percentage of viable cells, the
number of live, medium treated cells was divided by the number of
drug-treated cells.
Statistical Analysis
For in vitro experiments statistical analyses were performed on at
least 3 independent experiments using the student’s t-test or
ANOVA one-way analyses. For in vivo mouse experiments, a two-sided
Student t test was applied for comparison of continuous variables
between animal groups. Differences were considered significant
when the p values were,0.05.
Data from immunohistochemistry experiments were collected
from five random fields of stained sections using Image Pro
software version 4.5.0.29 (Media Cybernetics, Inc., Silver Spring,
MD). Each field was quantified as a percentage of positively
stained cells. Fields from the same tissue section were averaged and
SPSS software version 12.0.2 (SPSS, Inc., Chicago, IL) was used to
analyze the data.
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